

Ashay D Bhatwadekar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7271569/publications.pdf>

Version: 2024-02-01

37
papers

1,267
citations

516215

16
h-index

454577

30
g-index

38
all docs

38
docs citations

38
times ranked

1658
citing authors

#	ARTICLE	IF	CITATIONS
1	Circadian rhythm disruption results in visual dysfunction. <i>FASEB BioAdvances</i> , 2022, 4, 364-378.	1.3	1
2	Hypermethylation of miRNA-17-92 cluster in peripheral blood mononuclear cells in diabetic retinopathy. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102390.	1.8	0
3	Dapagliflozin protects neural and vascular dysfunction of the retina in diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002801.	1.2	3
4	RNA therapeutics for retinal diseases. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 603-613.	1.4	15
5	Retinal Phenotyping of Ferrochelatase Mutant Mice Reveals Protoporphyrin Accumulation and Reduced Neovascular Response. , 2021, 62, 36.		3
6	Genetics of Diabetic Retinopathy, a Leading Cause of Irreversible Blindness in the Industrialized World. <i>Genes</i> , 2021, 12, 1200.	1.0	25
7	Diabetic Retinopathy in the Aging Population: A Perspective of Pathogenesis and Treatment. <i>Clinical Interventions in Aging</i> , 2021, Volume 16, 1367-1378.	1.3	39
8	Anti-integrin therapy for retinovascular diseases. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 935-945.	1.9	32
9	Circadian rhythms in diabetic retinopathy: an overview of pathogenesis and investigational drugs. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1431-1442.	1.9	8
10	Metformin Corrects Abnormal Circadian Rhythm and Kir4.1 Channels in Diabetes. , 2020, 61, 46.		23
11	Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 237-244.	1.9	17
12	The Diurnal Rhythm of Insulin Receptor Substrate-1 (IRS-1) and Kir4.1 in Diabetes: Implications for a Clock Gene <i>Bmal1</i> . , 2019, 60, 1928.		12
13	Effect of the pharmacist-managed cardiovascular risk reduction services on diabetic retinopathy outcome measures. <i>Pharmacy Practice</i> , 2019, 17, 1319.	0.8	6
14	Diabetes Alters Diurnal Rhythm of Electroretinogram in db/db Mice. <i>Yale Journal of Biology and Medicine</i> , 2019, 92, 155-167.	0.2	3
15	Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in <i>db/db</i> Mice. <i>Diabetes</i> , 2018, 67, 1867-1879.	0.3	243
16	Advanced glycation end (AGE) product modification of laminin downregulates Kir4.1 in retinal Müller cells. <i>PLoS ONE</i> , 2018, 13, e0193280.	1.1	17
17	Conditional Deletion of <i>Bmal1</i> Accentuates Microvascular and Macrovascular Injury. <i>American Journal of Pathology</i> , 2017, 187, 1426-1435.	1.9	34
18	Hematopoietic stem/progenitor involvement in retinal microvascular repair during diabetes: Implications for bone marrow rejuvenation. <i>Vision Research</i> , 2017, 139, 211-220.	0.7	21

#	ARTICLE	IF	CITATIONS
19	Tumor Necrosis Factor Alpha (TNF- α) Disrupts Kir4.1 Channel Expression Resulting in Müller Cell Dysfunction in the Retina. , 2017, 58, 2473.		16
20	Per2-Mediated Vascular Dysfunction Is Caused by the Upregulation of the Connective Tissue Growth Factor (CTGF). PLoS ONE, 2016, 11, e0163367.	1.1	12
21	Ataxia Telangiectasia Mutated Dysregulation Results in Diabetic Retinopathy. Stem Cells, 2016, 34, 405-417.	1.4	12
22	miR-92a Corrects CD34+ Cell Dysfunction in Diabetes by Modulating Core Circadian Genes Involved in Progenitor Differentiation. Diabetes, 2015, 64, 4226-4237.	0.3	27
23	CNS Inflammation and Bone Marrow Neuropathy in Type 1 Diabetes. American Journal of Pathology, 2013, 183, 1608-1620.	1.9	53
24	Per2 Mutation Recapitulates the Vascular Phenotype of Diabetes in the Retina and Bone Marrow. Diabetes, 2013, 62, 273-282.	0.3	61
25	Activation of the ACE2/Angiotensin-(1-7)/Mas Receptor Axis Enhances the Reparative Function of Dysfunctional Diabetic Endothelial Progenitors. Diabetes, 2013, 62, 1258-1269.	0.3	91
26	Enhancing the Function of CD34+ Cells by Targeting Plasminogen Activator Inhibitor-1. PLoS ONE, 2013, 8, e79067.	1.1	12
27	Liver X Receptor Modulates Diabetic Retinopathy Outcome in a Mouse Model of Streptozotocin-Induced Diabetes. Diabetes, 2012, 61, 3270-3279.	0.3	62
28	Bone marrow-CNS connections: Implications in the pathogenesis of diabetic retinopathy. Progress in Retinal and Eye Research, 2012, 31, 481-494.	7.3	50
29	Promise of endothelial progenitor cell for treatment of diabetic retinopathy. Expert Review of Endocrinology and Metabolism, 2010, 5, 29-37.	1.2	8
30	Transient Inhibition of Transforming Growth Factor- β 1 in Human Diabetic CD34+ Cells Enhances Vascular Reparative Functions. Diabetes, 2010, 59, 2010-2019.	0.3	35
31	Differential Expression of Transforming Growth Factor Beta Receptor 2 (TGF β 2R2) In Diabetic CD34+ Cells: Implications for Vascular Repair. Blood, 2010, 116, 4795-4795.	0.6	4
32	Inhibition of Plasminogen Activator Inhibitor (PAI)-1 Corrects Diabetic CD34+ Dysfunction.. Blood, 2010, 116, 1601-1601.	0.6	1
33	Retinal Endothelial Cell Apoptosis Stimulates Recruitment of Endothelial Progenitor Cells. , 2009, 50, 4967.		20
34	Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. Journal of Experimental Medicine, 2009, 206, 2897-2906.	4.2	219
35	Advanced glycation of the Arg-Gly-Asp (RGD) tripeptide motif modulates retinal microvascular endothelial cell dysfunction. Molecular Vision, 2009, 15, 1509-20.	1.1	17
36	Advanced Glycation of Fibronectin Impairs Vascular Repair by Endothelial Progenitor Cells: Implications for Vasodegeneration in Diabetic Retinopathy. , 2008, 49, 1232.		58

#	ARTICLE	IF	CITATIONS
37	AGE and RAGE inhibitors in the treatment of diabetic retinopathy. Expert Review of Ophthalmology, 2007, 2, 105-120.	0.3	7